Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
The group’s Braftovi/Mektovi combo shows the potential of a targeted approach in colorectal cancer, so where is the competition?
The companies’ DS-8201 succeeds in breast cancer patients who had failed Kadcyla, and will go before the regulators later this year.
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
Array Biopharma hopes for a label extension for its Braf/Mek inhibitor, and Proteon tries to make a better fist of its second phase III trial of vonapanitase.
At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
Amid market volatility, biotech’s best friend comes through once again: the FDA has authorised a bumper 53 new medicines so far in 2018 and several more are expected…
Discontinuations and an unusual revelation about Tecentriq’s breast cancer data dominated the R&D part of the company’s third-quarter results call.